Recruiting

Gixam Device

Sponsor:

Jubaan Ltd.

Code:

NCT07623902

Conditions

CRC Screening

Microbiome

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Interventions

Gixam System

FIT

Standard of care screening colonoscopy

Study Details

Brief summary:

The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged 45-84 that are of average risk to develop colorectal cancer and have received a negative result on a Fecal Immunochemical Test (FIT). The main questions it aims to answer are:

1. Is the Gixam Device effective in identifying persons with pre-cancer or cancer in the colon and rectum that have received a negative FIT result?
2. Is the use of the Gixam device safe?

Gixam test result will be compared to the findings of a standard of care screening colonoscopy.

Study participants will:

1. Undergo the Gixam test
2. Take a FIT at home and ship to a laboratory.
3. Undergo a standard of care screening colonoscopy.

Conditions

CRC Screening

Microbiome

Study ID

NCT07623902

Start date

May 18, 2026

Status verified date

May, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Participants aged ≥45 - ≤84 years.
2. Able to provide a signed informed consent.
3. Considered by a physician or healthcare provider as being of 'average risk' for CRC.
4. Scheduled for a screening colonoscopy at investigation site.

Exclusion Criteria:

1. Undergoing colonoscopy for investigation of symptoms.
2. Has undergone colonoscopy within preceding nine (9) years except for a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention.
3. Positive FIT or Fecal Occult Blood Test (FOBT) result within the preceding eleven (11) months.
4. Has completed Cologuard, Sheild, ColoSense or Epi proColon testing within the preceding three (3) years.
5. History of colorectal cancer.
6. Family history of colorectal cancer, defined as having one or more first- degree relatives (parent, sibling, or child) with CRC at any age.
7. Participant has a diagnosis or medical / family history of any of the following conditions, including:

  • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome)
  • Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
  • Other hereditary cancer syndromes including but not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.
8. Participant has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
9. Participants with a disability to extend their tongue.
10. Participants with tongue tremor.
11. Participants with tongue piercing.
12. Participants that had a dental visit in the 7 days prior to the Gixam test.
13. Participants that have taken antibiotics or anti-fungal medications in the 14 days prior to the Gixam test.
14. Participants that have taken anti-inflammatories or probiotics in the 14 days prior to the Gixam test.
15. Participant is pregnant.
16. Participant has any condition that in the opinion of the Investigator should preclude participation in the study.

Study Design

Enrollment

1436 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

experimental: Intervention arm

All enrolled participants will undergo the same intervention: Gixam test, FIT, and screening colonoscopy

Interventions

Gixam System

All participant will undergo the Gixam test per device instructions for use

FIT

FIT kit will be handed out to the study participant, who will later sample stool at home and mail the specimen to a reference laboratory for analysis.

Standard of care screening colonoscopy

All participants will undergo a standard of care screening colonoscopy which serves as the gold truth in this study

Primary outcome measure

  • Primary Safety Endpoint [ Time Frame: From enrollment to the end of study at 30 days after ]
  • Primary Efficacy Endpoints [ Time Frame: Through study completion, an average of 30 days ]

Central Contacts and Locations

Locations

Orlando Gastroenterology, PA

Recruiting

Orlando, Florida, United States, 32835

Contacts

Comprehensive Gastrointestinal Health, LLC

Recruiting

Northbrook, Illinois, United States, 60062

Contacts

Westchester Putnam Gastro

Recruiting

Carmel, New York, United States, 10549

Contacts

Great Lakes Gastroenterology Research, LLC

Recruiting

Mentor, Ohio, United States, 44060

Contacts

Blue Ridge Medical Research

Recruiting

Lynchburg, Virginia, United States, 24502

Contacts

More Information

Sponsor

Jubaan Ltd.

Last update posted

Jun 3, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jubaan Ltd. on 2026-06-03.